Companies export psilocybin internationally through highly regulated business-to-business (B2B) channels that support scientific research, clinical trials, and approved medical applications. Because psilocybin is classified as a controlled substance in most jurisdictions, manufacturers and exporters must comply with national regulations as well as international drug control treaties governing its production and distribution.
To facilitate legal export, companies are required to obtain the appropriate export permits, ensure compliance with rigorous pharmaceutical manufacturing standards, and coordinate with authorised importers in the destination country. Secure packaging, controlled logistics, comprehensive documentation, and strict chain-of-custody procedures are also essential to ensure safe and compliant cross-border transit. This regulatory framework helps maintain product integrity while supporting the advancement of psychedelic research and therapeutic development worldwide.
